FAQ

BR96-doxorubicin immunoconjugate

Known as: cBR96-DOX, DOX-MOAB BR96, cBR96-doxorubicin conjugate 
An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin. The antibody moiety… (More)

Topic mentions per year

Topic mentions per year

1992-2017
02419922017

Related topics

Related topics

4 relations

Narrower (2)

BMS 182248SGN-15

Broader (2)

DoxorubicinMonoclonal Antibodies

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
BR96-doxorubicin immunoconjugate
Monoclonal Antibodies
Doxorubicin
SGN-15
BMS 182248

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model.
PURPOSE The objective of this study was to evaluate the efficacy of sequencing radiation therapy (RT) and antibody targeted… (More)
Is this relevant?
Review
2001
Review
2001
Development and activities of the BR96-doxorubicin immunoconjugate.
 
Is this relevant?
2000
2000
Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.
OBJECTIVE To evaluate dose intensification with osmotic blood-brain barrier disruption (BBBD) and the potential use of drug… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
PURPOSE BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately… (More)
Is this relevant?
1997
1997
Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248)
Purpose: The chimeric BR96–doxorubicin (DOX) immunoconjugate, BMS 182248, has induced remissions and cures of human lung… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
1997
1997
Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
The internalizing monoclonal antibody BR96 was conjugated to the anticancer drug doxorubicin (DOX) using an acid-labile hydrazone… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
1996
Review
1996
Immunoconjugates and immunotoxins for therapy of solid tumors
Immunoconjugates and immunotoxins are attracting attention as potential cancer therapeutic agents; however, monoclonal antibodies… (More)
Is this relevant?
1995
1995
Stabilization of Chimeric BR96-Doxorubicin Immunoconjugate
Chimeric BR96-doxorubicin conjugate (BR96-DOX) is an immunoconjugate designed to specifically target and kill certain tumor cells… (More)
Is this relevant?
1995
1995
Analysis of monoclonal antibody chimeric BR96-doxorubicin immunoconjugate by sodium dodecyl sulfate-capillary gel electrophoresis with ultraviolet and laser-induced fluorescence detection.
Sodium dodecyl sulfate-capillary gel electrophoresis (SDS-CAGE), the capillary version of SDS-polyacrylamide-based slab gel… (More)
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The… (More)
Is this relevant?